Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Temasek-led investor group in $250 million vaccine bet on Germany's BioNTech

Published 29/06/2020, 15:52
Updated 29/06/2020, 15:55
© Reuters. FILE PHOTO: The headquarters of biopharmaceutical company BioNTech are seen in Mainz

© Reuters. FILE PHOTO: The headquarters of biopharmaceutical company BioNTech are seen in Mainz

By Ludwig Burger

FRANKFURT (Reuters) - Singapore's state investor Temasek and other investors are injecting $250 million into German biotech company BioNTech (O:BNTX), which is developing an experimental vaccine against the coronavirus with pharmaceutical giant Pfizer (N:PFE).

The investment, which BioNTech said was via a private placement, reflects heightened investor interest in the race to develop an agent that will stop the pandemic and sent shares in biotech firms such as Moderna (O:MRNA) and Novavax (O:NVAX) soaring this year.

U.S.-listed shares in the German company jumped almost 15% to their highest since March 19 on the news. They have surged more than 80% so far this year against the Nasdaq biotech index's gain of 12%.

BioNTech, which went public on Nasdaq in October last year, said the investors would purchase about $139 million in ordinary shares and $112 million in 4-year mandatory convertible notes.

It has said it expects first clinical data on its COVID-19 vaccine development programme known as BNT162 this month or in July.

The transaction would increase the number of BioNTech shares outstanding by 2.6 million from 226.8 million shares as per end of March, resulting in a combined stake of 1.1% for the investor group once all notes are converted.

BioNTech, which is also working on personalised cancer vaccines, would not say how much of the total is attributed to Temasek. Temasek would also not comment.

The investment adds to Temasek's healthcare assets that include Singapore biotech firm and COVID-19 treatment developer Tychan, British biotech firm Orchard Therapeutics and Irish drug delivery firm Aerogen.

Life sciences and agribusiness made up 7% of Temasek's holdings in the year to March 2019, up from 3% in the year to 2015.

BioNTech and Pfizer launched testing programmes involving humans in April and May.

Domestic rival vaccine developer CureVac, in which the German government is taking a 23% stake, is planning an initial public offering in the United States next month. U.S. peer Translate Bio (O:TBIO) has attracted France's Sanofi (PA:SASY) as an investor in a deal worth as much as $2 billion.

BioNTech, which awarded the rights to BNT162 in China to Shanghai Fosun (SS:600196) under a March collaboration deal, is competing with CureVac as well as U.S. biotech firms Moderna (O:MRNA) and Translate Bio in the race to develop messenger-RNA vaccines.

© Reuters. FILE PHOTO: The headquarters of biopharmaceutical company BioNTech are seen in Mainz

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.